Farmakopöa töökava asjus

Signe Leito Saatja: [email protected] Saatmisaeg: neljapäev, 25. september 2025 16:34 Adressaat: Signe Leito Teema: Survey: proposed addition of Osimertinib mesilate and Osimertinib mesilate tablets to the WP: EDQM-2025-03783-mail Järeltegevuse lipp: Järeltegevus Olekulipp: Lipuga märgitud Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada. Please make sure to include in any reply our mail reference: EDQM-2025-03783-mail **************************************************************************** For the attention of NPAs Copy: Presidium Dear Colleagues, Please find below the link to a survey being carried out concerning the proposed addition of two monographs to the work programme of Group P4: Osimertinib mesilate and Osimertinib mesilate tablets In order to have access to the survey, please copy and paste this link into your Internet browser: https://survey.edqm.eu/index.php?r=survey/index&sid=154771&newtest=Y&lang=en Deadline for replies: 27 October 2025. Thank you. With kind regards On behalf of Aurélie Barth ___ Villy Nikolova Administrative Support Assistant European Pharmacopoeia Department EDQM Council of Europe Tel.: +33 (0)3 90 21 64 63 / Fax: +33 (0)3 88 41 27 71 https://www.edqm.eu / https://www.edqm.eu/store Stay connected with the EDQM **************************************************************************** Please make sure to include in any reply our mail reference: EDQM-2025-03783-mail 1